News
3 Growth Stocks I'd Buy Right Now
What's a six-letter word that's guaranteed to make investors happy? Growth. While growth comes in several flavors, they're all interrelated. Growth in revenue helps make earnings growth possible,....
Better Buy: Pfizer (PFE) vs. AbbVie (ABBV)
For Pfizer (NYSE: PFE), 2017 so far has looked better than the past couple of years in terms of stock performance. However, the stock's 9% year-to-date gain isn't anything to jump up and down....
The Individual Mandate: We Hate It, but We Need It
Big change is afoot in Washington, and it has nothing to do with the weather. Republicans in both houses of Congress have passed their respective version of tax reform and now are working on a few....
Will Johnson & Johnson Raise Its Dividend in 2018?
Just about everyone has some products from Johnson & Johnson (NYSE: JNJ) in their medicine cabinets, ranging from over-the-counter medicines like Tylenol and Benadryl to Band-Aid bandages. Yet....
Better Buy: Intuitive Surgical, Inc. vs. Accuray, Inc.
New drugs that improve treatment often get a lot of attention. But in recent years some medical devices have arguably had just as much impact as many of these drugs. Two companies making such....
Tax Reform Takes a Bite Out of Biotech Stocks
Healthcare companies will largely benefit from tax reform that lowers the statutory business tax rate to 20% from 35%, but those in research-intensive sectors such as biotechnology could end up....
Immunomedics' Data Is Good News for Seattle Genetics, Too
Seattle Genetics' (NASDAQ: SGEN) deal to license Immunomedics' (NASDAQ: IMMU) sacituzumab govitecan, a breast cancer drug, was shelved earlier this year when activist investor venBio Select....
It's Business as Usual at Veeva Systems Inc., and That's Good News for Shareholders
Veeva Systems (NYSE: VEEV) has quickly become a standard-bearer in the pharmaceutical industry. The company was born out of co-founder and CEO Peter Gassner's experience while an executive at....
Allergan Stock Downgraded: What You Need to Know
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one....
Is Exact Sciences Corporation (EXAS) a Buy?
Some investors look at a stock that has nearly quadrupled in price within less than 12 months and are excited about buying it. Others look at the same stock and are afraid that the momentum could....
Here's What Caused Sarepta Therapeutics to Shoot 13% Higher In November
A month full of news related to the progress it's making toward helping patients with Duchenne muscular dystrophy (DMD) sparked a 12.9% rally in Sarepta Therapeutics (NASDAQ: SRPT) shares last....
These 3 Healthcare Stock Dividends Could Soar If Trump Signs a Tax Reform Bill
Now that tax reform bills featuring 20% tax rates have passed the House and Senate, it looks like companies across the country will get to distribute a lot more of the profits they generate. Of....
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Better luck next year. That's what Merck & Co. (NYSE: MRK) is hoping for after a disappointing 2017. Merck stock is down year to date by 7%, while the S&P 500 index is up close to 18%.Will....
2 Top Consumer Staples Stocks to Consider Buying Now -- and 1 to Avoid
Recessions are common enough that you can count on several of them impacting your portfolio over the course of even a 10-year time horizon. That's just one reason why consumer staples stocks --....
This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November
Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biopharmaceutical company that develops treatments for eye disorders and other serious medical conditions, tumbled 10% during the....
Veeva Systems Inc. (VEEV) Q3 2018 Earnings Conference Call Transcript
Image source: The Motley Fool.Veeva Systems Inc. (NYSE: VEEV)Q3 2018 Earnings Conference CallDec. 5, 2017, 4:30 p.m. ETOperatorContinue readingSource: Fool.com
3 Growth Stocks With Virtual Monopolies
Monopolies can be bad. Having a single company control every aspect of an entire industry is likely to lead to higher consumer prices, slower innovation, and anticompetitive behavior.Lucky for us,....
Why Illumina Jumped 9.8% in November
Shares of the genomic sequencing specialist Illumina (NASDAQ: ILMN) rose nearly 10% in November, according to data from S&P Global Market Intelligence. However, there wasn't any....
Why Alexion Pharmacteuicals Sank 8.9% in November
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a commercial-stage biotech focused on rare diseases, fell 9% in November, according to data from S&P Global Market Intelligence. There doesn't....
3 Things Veeva Systems Inc. Shareholders Should Watch Going Into Earnings
Veeva Systems (NYSE: VEEV), which provides cloud solutions primarily to pharmaceutical companies, will be reporting earnings next week. While the stock has been a resounding success over the past....
What Happened in the Stock Market Today
Stocks began the day in positive territory thanks to optimism over the Senate's passage of a tax bill, but declined over the length of the session, ultimately ending with mixed results. The Dow....
Where Will Exact Sciences Corporation Be in 5 Years?
Roughly 18 months ago, Exact Sciences (NASDAQ: EXAS) was in rough shape. Cash was getting tight as the company spent aggressively to commercialize its new colon cancer test. Add in some troubling....
3 Reasons Pfizer Should Buy Celgene in 2018
You might think it's a crazy idea. Maybe it is a crazy idea. But sometimes crazy ideas are the ones that wind up being the best. So here it is: Pfizer (NYSE: PFE) should buy Celgene (NASDAQ: CELG)....
Why Intuitive Surgical, Inc. Shareholders Have Something to Worry About
Surgeons around the globe will perform around 867,000 procedures using Intuitive Surgical, Inc.'s (NASDAQ: ISRG) robots this year, making this company the undisputed champion of robotic surgery,....
What to Expect From Veeva Systems Inc. in 2018
You can't really complain about Veeva Systems (NYSE: VEEV) stock performance in 2017. The cloud-based software provider's share price is up more than 45% year to date. However, this impressive....